Indegene Share Price Today (INDGN)
TODAY IN ONE LINE
INDGN rose 1.9% on light volume, outperforming Nifty's 0.6% move, supported by recent strong earnings.
With a market cap of ₹12,095.91 Cr., it trades at a P/E of 29.69. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Indegene flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Capital EfficiencyROCE of 18.8% indicating pricing power
- ●Healthy Operating MarginsOPM is structurally strong at 17.6%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●FII AccumulationFII holding increased by 1.26% QoQ
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 32.3% YoY
- ●Rising Receivables vs SalesReceivables grew 18.4% outpacing sales growth of 9.6%
Latest Indegene News
What changed recently?
Recent events, corporate actions, and announcements.
Indegene Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Indegene Limited, framed against the sector median so the premium or discount is obvious at a glance.
Indegene Limited trades at a P/E of 29.69× and P/B of 3.79×, against the Healthcare sector median P/E of 44.57×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Indegene Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Indegene Limited — derived from the live tape, not yesterday's close.
Indegene Limited last traded at ₹502.05 with an intraday range of ₹491–₹503.95 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹502.05| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 532.90 | +30.85 | +6.14% |
| R3 | 519.95 | +17.90 | +3.57% |
| R2 | 511.95 | +9.90 | +1.97% |
| R1 | 507.00 | +4.95 | +0.99% |
| PIVOT | 499.00 | -3.05 | -0.61% |
| CURRENT | 502.05 | — | — |
| S1 | 494.05 | -8.00 | -1.59% |
| S2 | 486.05 | -16.00 | -3.19% |
| S3 | 481.10 | -20.95 | -4.17% |
| S4 | 468.15 | -33.90 | -6.75% |
INDGN is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹491–₹500.95
Trading Above opening range, showing Bullishness
Indegene Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Indegene Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Indegene Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹12,095.91 Cr. and reported EPS of ₹16.60.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 2,839 | 3,511 ▲ 23.6% |
| Sales Growth YoY %Derived | 9.64% | 23.64% |
| Other Income | 107 | 72 ▼ 32.8% |
| Total Income | 2,947 | 3,583 ▲ 21.6% |
| Gross ProfitDerived | 2,839 | 3,511 ▲ 23.6% |
| Gross Margin %Derived | 100.00% | 100.00% |
| 2,305 | 2,892 ▲ 25.4% | |
| EBITDA (Operating Profit)Derived | 534 | 619 ▲ 15.9% |
| OPM %Derived | 18.82% | 17.63% |
| 102 | 125 ▲ 22.7% | |
| Profit Before Tax (PBT) | 539 | 525 ▼ 2.7% |
| 133 | 124 ▼ 6.6% | |
| Effective Tax %Derived | 24.59% | 23.60% |
| Total Profit for Period | 407 | 401 ▼ 1.4% |
| Net Profit (Owner's PAT)Derived | 407 | 401 ▼ 1.4% |
| Net Profit Margin %Derived | 14.32% | 11.43% |
| PAT Growth YoY %Derived | 20.79% | -1.38% |
| Earnings Per Share (EPS ₹) | 16.95 | 16.65 ▼ 1.8% |
| Diluted Shares Outstanding (Cr) | 24 | 24 ▲ 0.4% |
| Other Comprehensive Income (Net of Tax) | 26 | 139 ▲ 444.5% |
| Total Expenses (incl. D&A & Interest) | 2,407 | 3,058 ▲ 27.0% |
| Material Cost % of RevenueDerived | — | — |
| Employee Cost % of RevenueDerived | 63.93% | 62.60% |
| Other Cost % of RevenueDerived | 17.25% | 19.76% |
| Interest Coverage (x)Derived | 20.64x | 25.52x |
| Period | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|
| Revenue from Operations | 2,590 | 2,839 ▲ 9.6% | 3,511 ▲ 23.6% | |
| Sales Growth YoY %Derived | — | 9.64% | 23.64% | |
| Other Income | 76 | 107 ▲ 40.5% | 72 ▼ 32.8% | |
| Total Income | 2,666 | 2,947 ▲ 10.5% | 3,583 ▲ 21.6% | |
| Gross ProfitDerived | 2,590 | 2,839 ▲ 9.6% | 3,511 ▲ 23.6% | |
| Gross Margin %Derived | 100.00% | 100.00% | 100.00% | |
2,084 | 2,305 ▲ 10.6% | 2,892 ▲ 25.4% | ||
| EBITDA (Operating Profit)Derived | 505 | 534 ▲ 5.7% | 619 ▲ 15.9% | |
| OPM %Derived | 19.52% | 18.82% | 17.63% | |
128 | 102 ▼ 20.1% | 125 ▲ 22.7% | ||
| Profit Before Tax (PBT) | 459 | 539 ▲ 17.6% | 525 ▼ 2.7% | |
122 | 133 ▲ 8.8% | 124 ▼ 6.6% | ||
| Effective Tax %Derived | 26.58% | 24.59% | 23.60% | |
| Total Profit for Period | 337 | 407 ▲ 20.8% | 401 ▼ 1.4% | |
| Net Profit (Owner's PAT)Derived | 337 | 407 ▲ 20.8% | 401 ▼ 1.4% | |
| Net Profit Margin %Derived | 13.00% | 14.32% | 11.43% | |
| PAT Growth YoY %Derived | — | 20.79% | -1.38% | |
| Earnings Per Share (EPS ₹) | 14.07 | 16.95 ▲ 20.5% | 16.65 ▼ 1.8% | |
| Diluted Shares Outstanding (Cr) | 24 | 24 ▲ 0.3% | 24 ▲ 0.4% | |
| Other Comprehensive Income (Net of Tax) | 8 | 26 ▲ 224.1% | 139 ▲ 444.5% | |
| Total Expenses (incl. D&A & Interest) | 2,207 | 2,407 ▲ 9.1% | 3,058 ▲ 27.0% | |
| Material Cost % of RevenueDerived | — | — | — | |
| Employee Cost % of RevenueDerived | 63.78% | 63.93% | 62.60% | |
| Other Cost % of RevenueDerived | 16.71% | 17.25% | 19.76% | |
| Interest Coverage (x)Derived | 8.69x | 20.64x | 25.52x |
Indegene segment analysis : revenue and profit mix.
Disclosed business segments at Indegene with their share of revenue and profit, switchable between consolidated and standalone reporting.
Indegene discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Indegene Limited.
Our AI distills the core fundamental drivers supporting Indegene Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Indegene Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
ROCE 18.80% and ROE 14.40% demonstrate efficient capital deployment and shareholder value creation.
Operating margin 14.03% TTM exceeds peers like Fabtech, signaling strong pricing power and efficiency.
TTM revenue growth 32.80% YoY significantly outpaces competitors, reflecting robust market demand.
Debt-to-equity 0.0005x with net debt negative ₹11,489 Cr provides exceptional financial flexibility.
Operating cash flow ₹345.60 Cr covers capex and dividend payouts, confirming high-quality earnings.
Key Risks.
Latest quarterly EPS declined 32.2% YoY despite revenue growth, indicating margin compression.
TTM EPS declined 32.3% YoY to ₹16.62, signaling near-term earnings pressure and profitability challenges.
P/E ratio 30.93x elevated versus forward P/E 20.46x, suggesting near-term overvaluation concerns.
Dividend yield 0.44% minimal, limiting income appeal for yield-focused investors.
Working capital swings negative ₹1,016 Cr in H1 2025, straining cash flow stability.
Flip Conditions.
Valuation risk. a P/E above 39 (~0.9× the sector multiple of 44.6) would leave less room for earnings disappointment.
Fundamental risk. a shrinking deal pipeline (TCV) or margins below historical averages would weaken the thesis.
Watch wage inflation and attrition rates — primary threats to operating leverage in IT.
Return-quality risk. ROE below 9% would indicate weaker capital compounding.
Indegene Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Indegene Limited is highlighted for quick read-across.
Quick Compare
Indegene Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Indegene Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Indegene Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Indegene Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Indegene Limited stood at 49.8% of traded volume, against a 20-day average of 56.1%.
Indegene announcements: results, concalls, ratings, M&A.
Filings Indegene sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Indegene files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 194 documents below.
Copy of Newspaper Publication
Indegene Limited has informed the Exchange about Copy of Newspaper Publication
General Updates
Indegene Limited has informed the Exchange about Letter to Shareholders in relation to Annual Report of the Company for the financial year 2025-26
General Updates
Indegene Limited has informed the Exchange about Business Responsibility and Sustainability Report for the financial year 2025-26
Shareholders meeting
Indegene Limited has informed the Exchange about Shareholders meeting
Copy of Newspaper Publication
Indegene Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
Analysts/Institutional Investor Meet/Con. Call Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Indegene dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Indegene has declared, sequenced by announce and record date.
Indegene corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Indegene insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Indegene as reported to SEBI — buying and selling signals from the people who know the business best.
Indegene insider activity below tracks 9 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Anita Nair | Insider | 19 Mar 2026 | buy | +22.2 K | ₹99.98 L | ₹449.76 |
| Anita Nair | Insider | 19 Mar 2026 | buy | +22.2 K | ₹99.98 L | ₹449.76 |
| Anita Nair | Insider | 19 Mar 2026 | buy | +22.2 K | ₹99.98 L | ₹449.76 |
| Anita Nair | Insider | 19 Mar 2026 | buy | +22.2 K | ₹99.98 L | ₹449.76 |
| Anita Nair | Insider | 19 Mar 2026 | buy | +22.2 K | ₹99.98 L | ₹449.76 |
| Manish Gupta | Insider | 24 Dec 2024 | buy | +17.0 K | ₹1.02 Cr. | ₹599.19 |
| Rajesh Bhaskaran Nair | Insider | 23 Dec 2024 | buy | +25.0 K | ₹1.5 Cr. | ₹598.26 |
| Sanjay Suresh Parikh | Insider | 20 Dec 2024 | buy | +16.5 K | ₹1 Cr. | ₹606.52 |
| Rajesh Bhaskaran Nair | Insider | 17 Dec 2024 | buy | +1.00 L | ₹5.96 Cr. | ₹595.81 |
About Indegene Limited: business, sector, key facts.
What Indegene Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Indegene Limited operates in the Healthcare Research Analytics & Technology industry under the Healthcare sector, listed as NSE: INDGN, BSE: 544172.
Indegene Limited is a global digital-first life sciences commercialization company headquartered in Bengaluru, India, with a significant presence in the United States and Europe. The company's core business revolves around providing comprehensive services and technology solutions to biopharmaceutical, emerging biotech, and medical device companies across their entire product lifecycles.
Indegene's operations are structured into three primary segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, and Omnichannel Activation & Others. The Enterprise Medical Solutions segment focuses on providing medical and clinical solutions, supporting the development and regulatory aspects of new products. This likely includes services such as medical affairs, regulatory strategy, and clinical trial support.
The Enterprise Commercial Solutions segment caters to the commercial aspects of bringing products to market. This likely encompasses services such as market research, sales force effectiveness, pricing and market access strategy, and overall commercial strategy development and execution. These services are crucial for maximizing product uptake and return on investment.
The Omnichannel Activation & Others segment likely incorporates a range of solutions aimed at integrating various channels for effective communication and engagement with healthcare professionals and patients. This might include digital marketing, content creation, and multi-channel campaign management to promote products and build brand awareness. The "Others" component likely encompasses additional services that complement the core offerings, potentially including consulting or specialized technology services.
A key aspect of Indegene's business model is its reliance on NEXT technology platforms. These platforms likely represent a suite of proprietary technologies and tools designed to enhance efficiency and effectiveness across its various service offerings. These platforms could include data analytics dashboards, CRM systems tailored for the life sciences industry, or other specialized software.
In summary, Indegene acts as a comprehensive partner for life sciences companies, providing a blend of consulting, technology, and services to navigate the complexities of research, development, and commercialization. Their integrated approach across medical, commercial, and omnichannel activation ensures a holistic support system for clients throughout the entire product lifecycle.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Suven Life Sciences (SUVEN) Share PricePeer
- Syngene International (SYNGENE) Share PricePeer
- Vimta Labs (VIMTALABS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Indegene Limited (INDGN).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Indegene Limited (INDGN)?
The current share price of Indegene Limited (INDGN) is ₹502.05. Today, the stock has gained by ₹9.40 (1.91%), trading in a range of ₹491 to ₹503.95. The stock opened at ₹491 with a trading volume of 26,940 shares.
02Is Indegene Limited stock a good investment for long-term?
Indegene Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹12,095.91 crores, P/E ratio of 29.69, ROE of 14.40%, and ROCE of 18.80%. The dividend yield stands at 0.46%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Indegene Limited stock?
The 52-week high price of Indegene Limited (INDGN) is ₹596.8, while the 52-week low is ₹414. Currently trading at ₹502.05, the stock is 48.2% away from its 52-week low and 15.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Indegene Limited stock at the current price?
Whether to buy Indegene Limited stock at ₹502.05 depends on multiple factors. The stock is currently trading with a P/E ratio of 29.69 and P/B ratio of 3.79. Today's performance shows a gain of 1.91%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Indegene Limited and when is the next dividend?
Indegene Limited offers a dividend yield of 0.46%, which means for every ₹100 invested at the current price of ₹502.05, you can expect to receive approximately ₹0.46 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Indegene Limited?
Indegene Limited's key financial metrics include: P/E Ratio: 29.69, P/B Ratio: 3.79, ROE: 14.40%, ROCE: 18.80%, Dividend Yield: 0.46%, EPS: ₹16.60, Book Value: ₹130.29, and Debt-to-Equity: 0.05. The company's market cap stands at ₹12,095.91 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Indegene Limited stock performing today in the market?
Indegene Limited stock opened at ₹491 and is currently trading at ₹502.05, showing a gain of ₹9.40 (1.91%). The intraday high is ₹503.95 and low is ₹491. The trading volume stands at 26,940 shares, indicating moderate market participation today.
08What is the P/E ratio of Indegene Limited and what does it indicate?
Indegene Limited has a Price-to-Earnings (P/E) ratio of 29.69, which means investors are willing to pay ₹29.69 for every ₹1 of earnings. With an EPS of ₹16.60, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Indegene Limited (INDGN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.